ACS
BMRN icon

Archford Capital Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Archford Capital Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,761
Closed -$338K – 268
2020
Q4 		$338K Buy
+3,761
New +$298K 0.08% 222

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Archford Capital Strategies's BMRN Position: Q1 2021 in Review

Archford Capital Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 3,761 shares — an estimated $338K sold.

Archford Capital Strategies first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $338K in Q4 2020. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Archford Capital Strategies reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Archford Capital Strategies sold 3,761 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $338K.
  • Archford Capital Strategies first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Archford Capital Strategies's BioMarin Pharmaceuticals position peaked at $338K in Q4 2020.
  • 531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Archford Capital Strategies's 13F filing for Q1 2021, filed 26 Apr 2021.